Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 19.88 CHF -1.58% Market Closed
Market Cap: 396.8m CHF

Wall Street
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 18.62 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

Lowest
Price Target
11.62 CHF
42% Downside
Average
Price Target
18.62 CHF
6% Downside
Highest
Price Target
26.25 CHF
32% Upside
Newron Pharmaceuticals SpA Competitors:
Price Targets
KLBF
Kalbe Farma Tbk PT
52% Upside
13
HUTCHMED (China) Ltd
59% Upside
1093
CSPC Pharmaceutical Group Ltd
33% Upside
CPH
Cipher Pharmaceuticals Inc
30% Upside
IOLCP
IOL Chemicals and Pharmaceuticals Ltd
34% Upside
LABB
Genomma Lab Internacional SAB de CV
50% Upside
MVP
Medical Developments International Ltd
67% Upside
ALM
Almirall SA
8% Upside

Revenue
Forecast

Revenue Estimate
Newron Pharmaceuticals SpA

For the last 13 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 49%. The projected CAGR for the next 3 years is -35%.

49%
Past Growth
-35%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

Net Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NWRN's stock price target?
Price Target
18.62 CHF

According to Wall Street analysts, the average 1-year price target for NWRN is 18.62 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
-35%

For the last 13 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 49%. The projected CAGR for the next 3 years is -35%.

Back to Top